High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Hui-Bo FengYu ChenZhi XieJie JiangYu-Min ZhongWei-Bang GuoWen-Qing YanZhi-Yi LvDan-Xia LuHong-Ling LiangFang-Ping XuJin-Ji YangXue-Ning YangQing ZhouDong-Kun ZhangZhou ZhangShao-Kun ChuaiHeng-Hui ZhangYi-Long WuXu Chao ZhangPublished in: Thoracic cancer (2021)
High SHP2 expression could predict the efficacy of immunotherapy and better survival in advanced KRAS mutant NSCLC. SHP2 may function in both tumor cells and immune cells, warranting further study on the potential diverse effects of SHP2 inhibition in TME.